SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (D)
of the
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported):  December 7, 2015

 
Arrayit Corporation
(Exact name of registrant as specified in its charter)

NEVADA
(State or other jurisdiction of incorporation or organization)
 
33-119586
76-0600966
(Commission File Number)
(IRS Employer Identification Number)

927 Thompson Place
Sunnyvale, CA  94085
(Address of principal executive offices)

Rene A. Schena
927 Thompson Place
Sunnyvale, CA  94085
(Name and address of agent for service)
408-744-1331
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 
 
 
 
SUNNYVALE, California – December 7, 2015 – Arrayit Corporation has received FINRA approval to dividend ten million common shares of its ownership in Avant Diagnostics, Inc. to all common shareholders of ARYC as of the record date October 30, 2015.  Payments shall be distributed as soon as practicable.
 
 
 
 
 
 

 
 
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Arrayit Corporation
 
       
Date:  December 7, 2015
By:
/s/ Rene A. Schena
 
   
Name: Rene A. Schena
 
   
Title: Chief Executive Officer
 
       

 
 
3

 


Exhibit 99.1
 
Arrayit Corporation Receives Approval for Ten Million Share Dividend in AVDX Stock to ARYC Shareholders
 
December 7, 2015 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences company, announces today it has received Financial Industry Regulatory Authority (FINRA) approval to dividend ten million common shares of its ownership in Avant Diagnostics (OTCQB: AVDX) to ARYC common shareholders as of the October 30, 2015 record date.  The present market value of the dividend is $2.6 million and there were approximately 450 million ARYC common shares outstanding as of the record date.  The dividend will be paid as soon as practicable.
 
Arrayit sells its patented and proprietary microarray platform to scientists and doctors worldwide to accelerate biomedical research, to discover safer and more effective medicines, and to develop rapid and affordable testing methods to improve human health and well-being.  Avant recently received Institutional Review Board (IRB) approval from the United States Food and Drug Administration (FDA) to validate ovarian cancer specimens pursuant to 510(k) approval of OvaDx(R), a pre-symptomatic ovarian cancer test that aids the monitoring of women diagnosed with ovarian cancer.  OvaDx(R) is exclusively manufactured by Arrayit and will be marketed and sold by Avant upon FDA approval.
 
Arrayit CEO Rene Schena states, “We are pleased to announce regulatory approval of the dividend, which underscores Arrayit’s commitment to creating shareholder value by leveraging our core microarray expertise and strengthening our ties with strategic partners.”
 
About Arrayit
 
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Please visit www.arrayit.com for more information.
 
Safe Harbor Statement
 
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2014 and in the Company's Forms 10-Q ended March 31, 2015, June 30, 2015 and September 30, 2015.
 
CONTACT
 
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
 
Arrayit (CE) (USOTC:ARYC)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Arrayit (CE) Charts.
Arrayit (CE) (USOTC:ARYC)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Arrayit (CE) Charts.